Akers Biosciences Inc. said full year loss from operations narrowed on a surge in revenues and said it expects to build its core product line sales both domestically and abroad and bring forward new and mass market potential diagnostic products.The diagnostic testing products developer said loss from operations for the full year to December 31, 2007, was $1.74 million compared to $8.83 million a year earlier.

Revenues for the period surged to $5.5 million from $1.4 million in the previous year due to the market penetration of its four core product lines.

Akers added the acquisitions completed in 2006 and early 2007 have established it as a leading player in the portable alcohol breathalyzer business in the United States.

Full story